Tag: Pollen
Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets
Under the terms of the Agreement, Altamira will initially supply Bentrio(TM) to Nuance. Nuance will make an upfront payment of $1 million and pay to Altamira development and commercial milestones of up to $3 million and up to $19.5 million, respectively. Nuance will have the right to register and commercialize Bentrio(TM) in the Territory. In a second stage, Nuance will assume local production of the product for the Territory upon certain milestones. Once Nuance assumes local production of Bentrio(TM), it will pay to Altamira a staggered royalty on net sales in the Territory at a high-single to low-double-digit percentage.
"We are excited to greatly expand the distribution of Bentrio and further enlarge our footprint in Asia through this strategic collaboration with Nuance," said Thomas Meyer, Altamira Therapeutics' founder, Chairman and CEO. "As a fast growing, well capitalized company with a growing portfolio of products specifically for the treatment of respiratory disorders, Nuance is an ideal commercialization partner for this important and dynamic region. We are looking forward to working with the Nuance team to launch Bentrio."
"The prevalence of allergic rhinitis in the Chinese Mainland is particularly high, affecting some 246 million patients[1]," commented Mark G. Lotter, CEO and Founder of Nuance. "In addition, viral infections represent another high-volume opportunity for Bentrio in this region, so we are looking forward to launching this promising therapeutic to patients in the Chinese Mainland; as well as Hong Kong, Macau and South Korea. Bentrio(TM) fits well with Nuance's continuous strategic focus in respiratory space."
References
[1] https://doi.org/10.4168/aair.2019.11.2.156
About Bentrio(TM)
Bentrio(TM)(AM-301) is a drug-free nasal spray intended for personal protection against airborne viruses and allergens. Upon application into the nose, Bentrio(TM) forms a protective gel layer on the nasal mucosa. This thin film is designed to prevent the contact of viruses or allergens with cells; in addition, the composition serves to bind such particles and help with their discharge and to humidify the nasal mucosa. Together, this is designed to reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms. In human nasal epithelium cells infected by SARS-CoV-2, Bentrio(TM) was shown to reduce the infectious viral load by more than 99% when used for prevention. Further, Bentrio(TM) was effective in slowing the growth of the viral titer when treatment started only 24 or 30 hours after infection. In allergy, a clinical investigation in a pollen challenge chamber demonstrated a significant reduction in the main symptoms of allergic rhinitis with the protective effect setting in rapidly and lasting for 4 hours.
About Nuance Pharma
Nuance Pharma is a patient-centric and innovation focused biopharmaceutical company, with both clinical and commercial stage assets. Founded by Mark Lotter in 2014, with the mission to address critical unmet medical needs in Greater China and Asia Pacific, Nuance has built a late clinical stage innovative portfolio, while maintaining a self-sustainable commercial operation. Focusing on specialty care, Nuance's portfolio represents a differentiated combination of commercial stage and innovative pipeline assets across respiratory, emergency care, and iron deficiency anemia. Through partnerships with global leading biopharma companies, Nuance has built a leading late-stage portfolio in respiratory and commercial stage portfolio in emergency care and iron deficiency anemia.
About Altamira Therapeutics
Altamira Therapeutics is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore(TM) / SemaPhore(TM) platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio(TM); commercial) or the treatment of vertigo (AM-125; Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen(R) and Sonsuvi(R), Phase 3). The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Altamira Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol "CYTO."
Forward-looking Statements
This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira Therapeutics' strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the approval, timing of commercialization and commercial success of AM-301, Altamira Therapeutics' need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Altamira Therapeutics' product candidates, the clinical utility of Altamira Therapeutics' product candidates, the timing or likelihood of regulatory filings and approvals, Altamira Therapeutics' intellectual property position and Altamira Therapeutics' financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Altamira Therapeutics' capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira Therapeutics' Annual Report on Form 20-F for the year ended December 31, 2020, and in Altamira Therapeutics' other filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking state ments and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or to persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira Therapeutics does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.
Investor contact:
Stephen Kilmer
(647) 872-4849
sjk@altamiratherapeutics.com
SOURCE: Altamira Therapeutics Ltd.
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comAltamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, announced today that it has entered into an exclusive licensing and distribution agreement (the "Agreement") for Bentrio(TM), its nasal spray for protection against airborne viruses and allergens, with Nuance Pharma Ltd. ("Nuance") in Chinese Mainland, Hong Kong, Macau and South Korea (the "Territory").
How to Make Cannabis Hashish Hassle-Freely
Many people often wonder how they can make cannabis hashish. Popularly shortened to hash, it is an Arabic name that means grass.
Over countless years, this concentrate from the cannabis plant has been utilized by many cultures for its beneficial properties.
Today, the growing curiosity about how to make cannabis hash prompts us to come up with an ultimate guide on how the process can be done in a straightforward manner.
Producing hash requires separating cannabis bud trichomes from the other plant parts. In female cannabis plants, there are frosty white hairy-like structures. In this case, that's what we refer to as trichomes.
These parts are highly abundant in THC, which is why they are the most desired part of the plant. Remember that to come up with viable hashish, you must extract substantial amounts of THC.
Kief Vs. Hashish
Hashish doesn't come merely from the separation of trichomes. The important factor at this point is kief.
Kief is the raw material that aids in the production of hashish. When heat and pressure are applied to kief, hashish comes into existence.
Making Kief into Hash
From kief, it's easy to come up with hash. There are two ways in which one can complete the process:
• Pollen pressing
• The heat and pressure method.
The Pollen Processing Method
Pollen Processing involves placing kief in a press. Next, you apply firm pressure to make it moldable. By applying direct pressure to the kief, you will create a basic hash (really a kief puck). This method makes it easier to come up with a puck of hash.
However, this method has disadvantages. The flavors do not get a chance to develop, as there is no heat used in the process. The heat assists in developing and maintaining the flavors of the hash in its finished form. Heating and applying pressure to kief gives you a higher-quality hash.
The Heat and Pressure Method
You can use the puck that you created above, or you can use cellophane to wrap kief and use a rolling pin to apply pressure and create a puck. Just keep gently applying pressure until the kief is at the density and shape that you want. You can continue to do this as long as you want. You can also let it sit for a day or two so that all of the flavors meld together. When you are ready, remove the cellophane
Once you have created a kief puck using a pollen press, to do the heat and pressure method, you will need to gently heat the kief. You will want to wrap the puck in a wet paper towel. You will then wrap the kief in a wrap that can withstand being in a 93 - 137°C (200 - 280°F) oven. A good cooking parchment paper will be perfect for this application.
Place the parchment paper and its contents in an oven set somewhere between 93 - 137°C (200 - 280°F). Make sure that the contents do not spill out. Having a baking sheet handy would be very helpful here. Place the package in your oven for 5-10 minutes. Unwrap the package. Rewet your paper towel, re-press your puck using the method above, and then rewrap it in parchment paper. Place this in the oven again for 5-10 minutes. Repeat the process. You want to do this whole process at least three times. Let it cool overnight or by placing the product in your fridge or freezer.
The pressure and heat method will produce a superior hash.
Methods Used in The Production of Hashish
There are other different methods used in coming up with hash. However, these ways give different potency levels.
It is also worth mentioning that different cannabis plants have different cannabinoid levels. That said, they can produce varied qualities of hash depending on the marijuana strain used. There are quite a few methods used to make cannabis hash. Nonetheless, we are going to give the three most used and cheap to try at home.
1. Finger Production Method
This could be described as the easiest method for producing hash.
As one harvests ganja from the cannabis plants, there may be instances where it sticks on the palms and the fingers.
The method involves placing a can or jar and rubbing your hands and fingers together over the can so that it collects the parts of the buds that stick to your hands. This can then be used to produce hash by rubbing your hands together vigorously. The heat and pressure produced during rubbing aid in combining the mixture into hash. However, this type of hash is described as having low quality. There may also be contamination coming from sweat and dirt on your hands.
The obtained hash may have off-flavors and unpredictable effects, which is a negative.
2. Silkscreen
This method involves sieving cannabis trichomes through a silkscreen. Depending on your preference, you can opt to make your silkscreen or purchase one.
Either way, note that the cannabis plant parts must be trimmed into very tiny sizes through this screen.
That said, you also need to ensure that you see the trichomes and collect them painstakingly. The finer the silkscreens that you use, the higher the probability of coming up with finely produced hashish.
One can opt to use the remains to sieve them further. However, the kief obtained from the get-go usually has mostly potent hashish.
Depending on the amount of hash needed, a single silkscreen is under most circumstances sufficient to come up with a substantial amount of hash.
3. Blender Method
The blender method relies heavily on probability. The colder the trichomes, the easier it gets to separate them from the rest of the cannabis plant parts.
Ice is a crucial ingredient in this method. Using this method involves mixing the cannabis plant matter, water, and ice into a blender.
Switching on the blender aids in separating the iced plant matter to get the trichomes. That becomes evident after switching off the blender. The trichomes sink, making it easy to obtain them promptly.
A sieve can then get used. The trichomes penetrate easily, which is why they pass through the sieve with the water while the rest of the plant parts remain on the sieve.
Letting the trichomes and water mixture cool for 30 minutes afterward helps the trichomes form a layer at the bottom.
However, one ought to be careful because slight disturbance to the trichomes can lead to unnecessary impurities.
The trichomes layer can then get placed in a freezer for ten minutes.
In Summary
Making hash is a sure way to make trichomes usable in a unique way. Now that you have the info necessary to come up with these concentrates, the ball is in your court.
The marijuana strains you use to extract the trichomes play an essential role in the overall effects obtained after using hashish. The better the strain you use, the better your hash will be.
Follow the method of your choice and enjoy your hash to the fullest!
Latest Intelligence
